Neural Noise

Non-invasive neuromodulation options for Parkinson's disease

2 min read

  • Non-invasive neuromodulation options (e.g. tDCS) for Parkinson’s disease are being explored alongside DBS for device and therapy roadmaps.1
  • The American Parkinson Disease Association has published exploratory/review content on these options.1 1

Gardner updates

  • A Nature review summarizes advancements in invasive (DBS) and non-invasive (tDCS, tACS) neuromodulation for Parkinson’s disease, with current findings, future directions, and an implementation path for device and trial prioritization. 2

  • The American Parkinson Disease Association (APDA) published an exploration of non-invasive neuromodulation options for Parkinson’s disease, including tDCS, informing device and therapy roadmaps alongside DBS. 1

  • A Nature review covers advancements in invasive (DBS) and non-invasive (tDCS, tACS) neuromodulation for Parkinson’s disease with implementation path and future directions . 2

Weekly enrichment (2026-07-20)

  • The American Parkinson Disease Association (APDA) describes three non-invasive neuromodulation approaches under investigation for PD—transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS) and low-intensity focused ultrasound (LIFU)—distinguishing them from the approved but invasive DBS and focused ultrasound.3
  • Per APDA, tDCS delivers a weak, constant current through two scalp electrodes (commonly over motor cortex or DLPFC), is portable and being explored for supervised at-home use, but is not FDA-approved for any condition and has shown mixed results in PD.3
  • Typical tDCS protocols apply 1-2 mA for 10-30 min; anodal motor-cortex stimulation has improved motor function and DLPFC stimulation cognition in some studies, though efficacy depends on stimulation intensity, duration, electrode placement and individual patient characteristics.4
  • A systematic review and meta-analysis in npj Parkinson’s Disease found tDCS did not differ significantly from sham overall; meta-regression indicated small positive effects (effect size ≈0.32) in mild motor symptoms (UPDRS-III ~13), null effects at moderate severity (UPDRS-III 22-25), and small-to-medium negative effects (≈-0.48) in severe patients.5
  • Transcranial electrical stimulation (tDCS/tACS) effects are attributed to changes in cell-membrane potentials, neurotrophic signaling and LTP/LTD-type plasticity; tACS specifically modulates oscillatory dynamics and sits at an earlier research stage than tDCS.54
  • Reviews note non-invasive options (rTMS, tDCS, tACS) are relatively inexpensive, portable and low-adverse-effect, making them attractive adjuvants to standard levodopa and DBS therapy, even though evidence for clinical efficacy remains largely insufficient.4
  • Implication for device and therapy roadmaps: APDA emphasizes these techniques are not yet available treatments and require more research to establish clinical utility, positioning them as experimental adjuncts alongside approved DBS rather than replacements.3

Footnotes

  1. https://news.google.com/rss/articles/CBMigwFBVV95cUxPRllMR2ItVG4zelBuNmVaX1VRTXNjTlFRbGlPN05FRi1pZTRFOUpVVUVsNnhVRDQ5SnNKSGRNdzhBLTdSN3gyTG9xUE96aGFKczhoRHEzT1lOWTlaNGViMXZrSUQyaG92dzF0WWNUSUd5ME9ZTm9odm1MU2I3Q0VjaE5Ecw?oc=5 ↩ ↩2 ↩3 ↩4

  2. https://news.google.com/rss/articles/CBMiX0FVX3lxTFBTR3hyMGhHYXlfN1pUWjJVS1dZc2Q3ZzdJa0NBeVJJaHRMNXExUWZ0ZmI0R19pVHpUR0hRSW1nYlJGbkZXcnZVNVNELXdaOUY0aEIwdVBtYVJXY2pkazNv?oc=5 ↩ ↩2

  3. https://www.apdaparkinson.org/article/neuromodulation-for-parkinsons-disease/ ↩ ↩2 ↩3

  4. https://www.sciencedirect.com/science/article/pii/S1878747924000163 ↩ ↩2 ↩3

  5. https://www.nature.com/articles/s41531-024-00821-z ↩ ↩2

Graph View